Clinical Trials Logo

Clinical Trial Summary

The current study is a phase II multi-center single arm trial to evaluate the efficacy and safety of low-dose radiotherapy (3 Gy*4f) in indolent lymphoma.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05543070
Study type Interventional
Source Chinese Academy of Medical Sciences
Contact
Status Recruiting
Phase Phase 2
Start date May 1, 2022
Completion date January 1, 2025

See also
  Status Clinical Trial Phase
Not yet recruiting NCT03261349 - Antiviral Agent HARVONI® for the Treatment of HCV-associated Indolent B-Cell Lymphoma Phase 2
Active, not recruiting NCT03133221 - 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation Phase 2
Recruiting NCT05003141 - PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies Phase 1
Recruiting NCT00687778 - 11C-Acetate PET/CT Non-FDG-Avid Tumors N/A
Active, not recruiting NCT04431635 - Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma Phase 1
Completed NCT00980395 - Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma Phase 2
Recruiting NCT04957693 - Effect of Vegan Diet and Lifestyle Changes on Indolent Lymphoma During Controlled Waiting Period N/A
Terminated NCT00954005 - Study With Rituximab-Gemcitabine/Oxaliplatin in Relapsed Indolent Lymphoma Phase 1/Phase 2
Completed NCT03424603 - Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies Phase 1
Completed NCT01263899 - A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies Phase 2
Recruiting NCT05020678 - NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers Phase 1
Active, not recruiting NCT04806035 - Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia Phase 1